Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus amylovorus

What does the research say about Lactobacillus amylovorus?

3 health outcomes synthesised

Lactobacillus amylovorus has been researched across 3 health outcomes: improved growth performance, reduced inflammation, and improved intestinal barrier function. The strongest evidence area is improved growth performance, where all 4 studies reported beneficial effects, though the evidence base is small and predominantly in animal models such as weaning pigs and lambs. Doses and forms were not consistently reported across studies, limiting practical application.

Strongest evidence: No outcomes reached high or moderate evidence strength; all three syntheses have low evidence strength. The most consistent findings are for improved growth performance, with all 4 studies reporting beneficial effects (effect sizes ranged from small to large) and 3 of 4 achieving statistical significance. For reduced inflammation, all 4 studies also reported benefits, including a meta-analysis of 25 RCTs showing a small but significant reduction in C-reactive protein (-0.99 mg/L).

Mixed or weaker evidence: All three outcomes rely on low evidence strength due to small study counts (3–4 studies each), animal models, or indirect human data. Evidence for improved intestinal barrier function is limited to 3 animal studies (piglets, sows, lambs), with moderate effect sizes but no direct human data.

Effective dose patterns: No consistent dose ranges were identified across any of the outcomes. Most studies did not report doses or forms, and no cross-cutting dose convergence was observed.

Population insights: The majority of studies involved non-human populations, such as weaning pigs, newborn piglets, lambs, fish, and mice. The only human-level evidence comes from a meta-analysis on inflammation that aggregated multiple postbiotics, making the benefit specific to Lactobacillus amylovorus unclear.

Notable caveats: All three syntheses flag a small evidence base (3–4 studies each) and potential publication bias, as null-result studies are less likely to be published. Animal-to-human generalizability is limited, and human data for Lactobacillus amylovorus specifically is sparse.

Frequently asked

  • What is Lactobacillus amylovorus good for according to research?
    Research shows potential benefits in three areas: improved growth performance (4 studies, all positive), reduced inflammation (4 studies, including a meta-analysis showing a small reduction in C-reactive protein), and improved intestinal barrier function (3 animal studies). However, all evidence is low strength and preliminary.
  • What dose of Lactobacillus amylovorus is typically used in studies?
    No consistent dose range was reported across the studies for any of the three outcomes. Most studies did not provide specific doses or forms of Lactobacillus amylovorus, making practical dosing recommendations unsupported by the current research.
  • Who benefits most from Lactobacillus amylovorus?
    The available research primarily involves animal populations, such as weaning pigs, newborn piglets, lambs, and fish. The only human evidence comes from a meta-analysis on inflammation, which aggregated multiple postbiotics; thus, specific human populations likely to benefit are not yet identified.
  • Are there caveats or limitations in the research on Lactobacillus amylovorus?
    Yes, several caveats exist: the evidence base is small (3–4 studies per outcome), all evidence strength is low, publication bias is likely (positive results are overrepresented), and most studies are in animals or cell cultures, limiting human applicability. Additionally, doses were often unreported.
  • Does Lactobacillus amylovorus help with improved growth performance?
    All 4 studies reported beneficial effects on growth performance, with 3 achieving statistical significance. Effect sizes were mixed (small, moderate, large). However, studies involved animals (pigs, lambs, fish), and human evidence for growth performance is lacking.
  • Does Lactobacillus amylovorus help with inflammation?
    A meta-analysis of 25 RCTs found a small but significant reduction in C-reactive protein (-0.99 mg/L) with postbiotics, but Lactobacillus amylovorus was not the sole agent. Three additional animal studies showed moderate anti-inflammatory effects, but human-specific evidence for this probiotic is limited.

Most-studied combinations with Lactobacillus amylovorus

most supplement research is combination research
Also studied with:Lactobacillus acidophilus (2)
Back to top